Stockscreener 앱 받기
8.20
0.99%
0.08
시간 외 거래:
8.25
0.05
+0.61%
전일 마감가:
$8.12
열려 있는:
$8.07
하루 거래량:
270.68K
Relative Volume:
1.54
시가총액:
$213.23M
수익:
$26.00M
순이익/손실:
$-219.71M
주가수익비율:
-0.1647
EPS:
-49.8
순현금흐름:
$-51.37M
1주 성능:
+21.30%
1개월 성능:
+3.80%
6개월 성능:
-40.45%
1년 성능:
-51.54%
1일 변동 폭
$7.67
$8.34
1주일 범위
$6.62
$8.34
52주 변동 폭
$5.98
$20.12
Cartesian Therapeutics Inc Stock (RNAC) Company Profile
명칭
Cartesian Therapeutics Inc
전화
301-348-8698
주소
7495 NEW HORIZON WAY, FREDERICK
RNAC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RNAC
Cartesian Therapeutics Inc
|
8.20 | 211.15M | 26.00M | -219.71M | -51.37M | -49.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-09 | 개시 | Wedbush | Outperform |
| 2024-12-19 | 개시 | BTIG Research | Buy |
| 2024-08-06 | 개시 | TD Cowen | Buy |
| 2024-07-02 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-06-04 | 개시 | Oppenheimer | Outperform |
| 2024-05-24 | 개시 | Mizuho | Buy |
| 2024-04-23 | 재확인 | H.C. Wainwright | Buy |
| 2024-04-23 | 개시 | Leerink Partners | Outperform |
| 2023-08-18 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2022-06-14 | 재확인 | Needham | Buy |
| 2022-06-06 | 개시 | SVB Leerink | Outperform |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-01-26 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-10-01 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-10-01 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2020-06-12 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-04-28 | 개시 | H.C. Wainwright | Buy |
| 2020-01-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-01-21 | 개시 | William Blair | Outperform |
| 2018-06-27 | 개시 | Janney | Buy |
| 2017-03-30 | 재확인 | UBS | Buy |
모두보기
Cartesian Therapeutics Inc 주식(RNAC)의 최신 뉴스
Cartesian Therapeutics (RNAC): Needham Raises Price Target to $4 - GuruFocus
Myasthenia Gravis Market Positioned for Accelerated - openPR.com
Cartesian Therapeutics highlights recent progress and outlines 2026 outlook - MarketScreener
Cartesian Therapeutics Reports Progress in Phase 3 AURORA Trial of Descartes-08 for Myasthenia Gravis and Initiates Pediatric Trial for Juvenile Dermatomyositis - Quiver Quantitative
Cartesian Therapeutics Highlights 2026 Strategic Priorities - TradingView — Track All Markets
Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook - GlobeNewswire
Cell therapy shows immune 'reset' potential in severe muscle disease - Stock Titan
What momentum indicators show for Cartesian Therapeutics Inc. stockQuarterly Portfolio Review & AI Optimized Trading Strategy Guides - ulpravda.ru
Is Cartesian Therapeutics Inc. stock resilient to inflationJuly 2025 Final Week & Growth Focused Stock Pick Reports - ulpravda.ru
Is Cartesian Therapeutics Inc. stock supported by innovation pipelineWeekly Stock Report & Free Technical Pattern Based Buy Signals - ulpravda.ru
Is Cartesian Therapeutics Inc. stock a buy before product launches2026 world cup usa national team quarterfinals defensive leaders transition play group prediction preview - ulpravda.ru
Johnson & Johnson Touts Encouraging Results For Experimental Lupus Treatment - Benzinga
Cartesian Therapeutics, Inc.Common Stock (NQ: RNAC - FinancialContent
Cartesian Therapeutics Announces New Employment Inducement Grants - The Manila Times
Biotech offering cell therapies uses stock options to lure new talent - Stock Titan
What analysts say about Cartesian Therapeutics Inc 1S70 stockPortfolio Allocation Tips & Small Investment Wealth Growth - earlytimes.in
Contrasting Beyond Air (NASDAQ:XAIR) & Cartesian Therapeutics (NASDAQ:RNAC) - Defense World
Working capital per share of Cartesian Therapeutics, Inc. – BER:1S70 - TradingView — Track All Markets
Does Cartesian Therapeutics Inc. stock trade at a discount to peersChart Signals & Daily Volume Surge Signals - Улправда
Cartesian Therapeutics Earnings Notes - Trefis
Why Cartesian Therapeutics Inc. stock is a value investor pickBear Alert & Proven Capital Preservation Methods - Улправда
What catalysts could drive Cartesian Therapeutics Inc. stock higherChart Signals & Daily Volume Surge Signals - Улправда
Aug Wrap: Why Cartesian Therapeutics Inc. (1S70) stock could be top winnerWeekly Gains Summary & Daily Volume Surge Trade Alerts - DonanımHaber
Can Cartesian Therapeutics Inc. stock maintain growth trajectoryQuarterly Market Review & AI Driven Stock Movement Reports - DonanımHaber
Earnings Recap: How Cartesian Therapeutics Inc. stock trades during market volatilityJuly 2025 Chart Watch & Reliable Breakout Forecasts - DonanımHaber
Cartesian Therapeutics Appoints Adrian Bot to Board of Directors - citybiz
How Cartesian Therapeutics Inc. stock performs in interest rate cyclesDay Trade & Expert Curated Trade Ideas - Улправда
Cartesian Therapeutics, Inc.(NasdaqGM:RNAC) dropped from NASDAQ Biotechnology Index - marketscreener.com
Is Cartesian Therapeutics Inc. stock in correction or buying zoneMarket Activity Report & Community Trade Idea Sharing - Улправда
Cartesian Therapeutics Appoints Dr. Adrian Bot to Board of Directors - Quiver Quantitative
Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors - The Manila Times
Will Cartesian Therapeutics Inc. stock deliver better than expected guidanceJuly 2025 Technicals & Low Risk Growth Stock Ideas - Улправда
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
683 Capital Management LLC Grows Stock Holdings in Cartesian Therapeutics, Inc. $RNAC - Defense World
Cartesian rebounds after insider purchase - MSN
Independent Director of Cartesian Therapeutics Picks Up 168% More Stock - simplywall.st
Cartesian Therapeutics (RNAC) Sees Share Boost After Insider Pur - GuruFocus
Cartesian stock rebounds after insider buy (RNAC:NASDAQ) - Seeking Alpha
Cartesian Therapeutics Director Purchases 30,000 Shares - TradingView — Track All Markets
Can Cartesian Therapeutics Stock Recover If Markets Fall? - Trefis
Here's Why We're Watching Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn Situation - Yahoo Finance
What MACD trends signal for Cartesian Therapeutics Inc. (1S70) stockPortfolio Return Summary & Reliable Volume Spike Alerts - Newser
Why Cartesian Therapeutics Inc. (1S70) stock stays undervaluedJuly 2025 Price Swings & Verified Momentum Stock Alerts - Newser
Weekly Earnings: What is the fair value estimate for Cartesian Therapeutics Inc 1S70 stock in 20252025 AllTime Highs & Reliable Volume Spike Trade Alerts - BỘ NỘI VỤ
What is the fair value estimate for Cartesian Therapeutics Inc. (1S70) stock in 2025Bond Market & Verified Momentum Stock Watchlist - Newser
Is Cartesian Therapeutics Inc. (1S70) stock a buy for dividend portfoliosEarnings Trend Report & Weekly Stock Breakout Alerts - Newser
Is Cartesian Therapeutics Inc. stock cheap at current valuationEarnings Growth Report & Real-Time Volume Analysis - Newser
Will Cartesian Therapeutics Inc. (1S70) stock outperform global peers2025 Big Picture & Technical Entry and Exit Alerts - Newser
Cartesian Therapeutics Inc (RNAC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Cartesian Therapeutics Inc 주식 (RNAC) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Miljkovic Milos | Chief Medical Officer |
Jan 06 '26 |
Sale |
6.82 |
3,573 |
24,367 |
58,820 |
| Davis Blaine | Chief Financial Officer |
Jan 06 '26 |
Sale |
6.82 |
10,591 |
72,227 |
121,220 |
| English Emily | Chief Operations Officer |
Dec 30 '25 |
Option Exercise |
3.30 |
7,500 |
24,750 |
70,226 |
| BARABE TIMOTHY C | Director |
Dec 04 '25 |
Buy |
6.86 |
30,000 |
205,797 |
54,366 |
| English Emily | Chief Operations Officer |
Nov 28 '25 |
Option Exercise |
3.30 |
7,500 |
24,750 |
62,726 |
0.90%
자본화:
|
볼륨(24시간):